Appco Pharma issues recall of ranitidine hydrochloride capsules 150 mg and 300 mg

Appco Pharma announced a voluntary, nationwide recall of all quantities and lots, within expiry, of ranitidine hydrochloride capsules. The recall is being undertaken due to the presence or potential presence of N-nitrosodimethylamine (NDMA) levels above the acceptable daily intake levels established by the FDA.

Appco Pharma announced a voluntary, nationwide recall of all quantities and lots, within expiry, of ranitidine hydrochloride capsules. The recall is being undertaken due to the presence or potential presence of N-nitrosodimethylamine (NDMA) levels above the acceptable daily intake levels established by the FDA. To date, Appco has received no reports of adverse events related to use of the product as part of the recall.